Reports Q4 revenue $200.7M, consensus $202.8M. “Our performance in 2024 reflects the strength of our core businesses, as Genomics continued to show strong volume growth and our Data business delivered record results throughout the year,” said Eric Lefkofsky, Founder and CEO of Tempus. “We believe our investments in AI have positioned us well for the future, as technologies that seemed unimaginable a few short years ago increasingly allow us to make our diagnostics intelligent, helping patients live longer and healthier lives. We remain on track to achieve our key financial milestones, with expected robust revenue growth and positive Adjusted EBITDA in 2025.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- tempus AI Inc Class A options imply 15.7% move in share price post-earnings
- Tempus AI, Stemline collaborate to leverage Next to help clinicians
- Tempus AI Transforms Healthcare with AI, TEM Stock Soars
- Insiders Dump Tempus AI (NASDAQ:TEM) Stock as Shares Notch Fresh Record Highs
- Tempus AI Stock (TEM) Hits New 52-Week despite Analyst Downgrade